Alzheimer's disease and the early signs of age-related macular degeneration

AuthorsFrost, S.
Guymer, R.
Aung, K. Z.
Macaulay, S. L.
Sohrabi, H. R.
Bourgeat, P.
Salvado, O.
Rowe, C. C.
Ames, D.
Masters, C. L.
Martins, R. N.
Kanagasingam, Y.
Group, A. T.
TypeJournal Article (Original Research)
JournalCurrent Alzheimer research
PubMed ID27335042
Year of Publication2016
URLhttp://www.ncbi.nlm.nih.gov/pubmed/27335042
DOIhttp://dx.doi.org/10.2174/1567205013666160603003800
AbstractThis study investigated signs of age related macular degeneration (AMD) in Alzheimer's disease (AD). These age-related diseases primarily affect different parts of the central nervous system but are substantially similar in terms of abnormal extracellular deposits, metabolic and oxidative stress, neuroinflammation and microvascular abnormalities. While AMD is a retinal disease, AD is reported to affect not only the brain but also the retina, with Abeta deposits, neurodegeneration and vascular changes. Large population based studies have provided conflicting results regarding the comorbidity of AD and AMD. This study investigated signs of AMD in a small but well characterized cohort from the Australian Imaging Biomarkers and Lifestyle study of aging (AIBL). The cohort consisted of 22 AD patients (age 70.2 +/- 9.0 yrs, 13 male, 9 female) and 101 cognitively normal (CN) participants (age 71.3 +/- 6.0 yrs, 40 male, 61 female). In comparison with the CN group, the AD group had a greater proportion of participants with early AMD (p < 0.0001, odds ratio 18.67, 95% CI 4.42 - 78.80). A logistic model for early AMD found a significant association with AD diagnosis (p < 0.0001), after adjusting for confounders (age, smoking, hypertension, high and low density lipoproteins, cataract surgery and APOE epsilon4 carrier status). The results of this study are consistent with an increased risk of AMD in AD. While the pathophysiology of these diseases are unclear, understanding the shared features between them may provide further knowledge about their pathogenesis and could lead to accelerated development of therapies for both diseases.

http://www.ibas.org.au/what-we-do/publications/3872826


< More publications



Respiratory Biomarkers in Motor Neurone DiseaseRESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE

The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...

Notch monitoring in sleepNOTCH MONITORING IN SLEEP

Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...

ResearchFest 2026RESEARCHFEST 2026

ResearchFest 2026 at Austin Health launched new research flagships and honored Professor Mark Howard (Distinguished Scientist) and Professor Eliza Hawkes (Women in Research Award), with insights from Peter Doherty.

Championing Sleep Research!CHAMPIONING SLEEP RESEARCH!

We are announcing exciting updates to our Early and Mid-Career Researcher (EMCR) representation at the Institute for Breathing and Sleep (IBAS). The MSRC extend a warm thank you to Charissa Zaga and welcome Jessica Manousakis!

ANZSRS Life Membership for Danny BrazzaleANZSRS LIFE MEMBERSHIP FOR DANNY BRAZZALE

Danny Brazzale has earned a prestigious ANZSRS Life Membership—held by only 11 people—for his global leadership and dedicated mentorship in respiratory science.

Perth Highlights: TSANZSRS 2026PERTH HIGHLIGHTS: TSANZSRS 2026

A huge congratulations to all our team members who participated in the excellent workshops and meetings at the TSANZSRS Annual Scientific Meeting in Perth in March 2026! Well Done!

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Health
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate